• Product nameAnti-Cdk4 antibody [DCS-31]
    See all Cdk4 primary antibodies
  • Description
    Mouse monoclonal [DCS-31] to Cdk4
  • SpecificityReacts specifically with Cdk4. Does not recognise other Cdk types.
  • Tested applicationsWB, IP, ICC, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant full length protein (Human).



Our Abpromise guarantee covers the use of ab6315 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 33 kDa (predicted molecular weight: 34 kDa).
IP Use at an assay dependent concentration.
ICC Use at an assay dependent concentration.
Flow Cyt 1/500. For 1 hour.


  • FunctionSer/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
  • Involvement in diseaseDefects in CDK4 are a cause of susceptibility to cutaneous malignant melanoma type 3 (CMM3) [MIM:609048]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
  • Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B.
  • Cellular localizationCytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Cdk 4 antibody
    • cdk4 antibody
    • CDK4 protein antibody
    • CDK4_HUMAN antibody
    • Cell division kinase 4 antibody
    • Cell division protein kinase 4 antibody
    • CMM 3 antibody
    • CMM3 antibody
    • Crk3 antibody
    • Cyclin dependent kinase 4 antibody
    • Cyclin-dependent kinase 4 antibody
    • Melanoma cutaneous malignant 3 antibody
    • MGC14458 antibody
    • p34 cdk4 antibody
    • PSK J3 antibody
    • PSK-J3 antibody
    see all

Anti-Cdk4 antibody [DCS-31] images

  • ab6315 staining human MDA-MB-436 breast cancer cells by Flow Cytometery. Cells were treated with Trypsin/EDTA for 5 minutes, sample buffer prepared as 5%FCS in PBS and gating was done on live non apoptotic cells. The primary antibody diluted 1/500 and incubated with sample for 1 hour at 4°C. A FITC conjugated horse polyclonal to mouse IgG, diluted 1/200 was used as secondary

References for Anti-Cdk4 antibody [DCS-31] (ab6315)

This product has been referenced in:
  • Scharfmann R  et al. Development of a conditionally immortalized human pancreatic ß cell line. J Clin Invest 124:2087-98 (2014). WB ; Human . Read more (PubMed: 24667639) »
  • Shi H  et al. Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5. J Clin Invest 123:2064-77 (2013). Flow Cyt ; Mouse . Read more (PubMed: 23543058) »

See all 5 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Flow Cytometry
Sample Human Cell (Melanoma cell line)
Specification Melanoma cell line
Fixation The cell suspension was rinsed twice with PBS and fixed with 70% ethanol at 20°C.
Permeabilization Yes - The cell suspension was rinsed twice with PBS and fixed with 70% ethanol at 20°C.
Gating Strategy Total Population.

Abcam user community

Verified customer

Submitted Feb 26 2013

Code de remise : xxxxxxxxxx
Date d’expiration : xxxxxxxxx

Je suis ravie que vous souhaitiez participer a notre offre et tester ab6315 en cytométrie en flux. Le code de réduction correspondant est xxxxxxxx.
Ce code ...

Read More

Thank you for your inquiry. I can confirm that ab3112 is sold in a concentration of 1mg/ml as stated on the datasheet. I can further also confirm that ab6315 has a concentration of no less than 10mg/ml. For the batch available a...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Flow Cytometry
Sample Human Cell (MDA-MB-436 breast cancer cells)
Specification MDA-MB-436 breast cancer cells
Preparation Cell harvesting/tissue preparation method: Trypsin/EDTA for 5 minutes
Sample buffer: 5% FCS in PBS
Permeabilization No
Gating Strategy live (non apoptotic cells) were selected

Dr. Penelope Ottewell

Verified customer

Submitted Dec 01 2008

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Tissue lysate - whole (Human breast tumour)
Loading amount 25 µg
Specification Human breast tumour
Treatment 2mg/kg doxorubicin and 0.1mg/kg zoledronic acid
Gel Running Conditions Reduced Non-Denaturing (Native) (10 % polyacrylamide gel)
Blocking step (agent) for 2 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 4°C

Dr. Penelope Ottewell

Verified customer

Submitted Jul 04 2008

This antibody has not been tested in this application. All the data that we have is presently on the datasheet.

We don't know the epitope of this antibody and have no data on whether the cdk4 is still active after immunoprecipitation.

This antibody has been tested in immunocytochemistry using cultured human tumour cell lines.